3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
2
Sarcoma
1
NET
1
Conditions
Sarcoma
16
Central Nervous System Neoplasms
10
Gliosarcoma
9
Glioblastoma
9
Osteosarcoma
8
Astrocytoma
6
Sarcoma, Ewing
5
Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma
3
Lung Neoplasms
3
Breast Neoplasms
3
Brain Neoplasms
3
Waldenstrom Macroglobulinemia
2
Stomach Neoplasms
2
Recurrence
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Oligodendroglioma
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Melanoma
2
Lymphoma, Extranodal NK-T-Cell
2
Liver Neoplasms
2
Leukemia, Myelomonocytic, Juvenile
2
Leukemia
2
Glioma
2
Esophageal Neoplasms
2
Dendritic Cell Sarcoma, Interdigitating
2
Colorectal Neoplasms
2
Interventions
tivozanib
1
repotrectinib
1
pembrolizumab
1
dostarlimab
1
atezolizumab
1
Fluorodeoxyglucose F18
1
Drug Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Neuroendocrine
×
Drug Therapy
×
Sarcoma
×
Clear all
NCT06333314
2025-12-02
Pan-MSI-ACSE
UNICANCER
Phase 2
Recruiting
120 enrolled